Compare Cassava Sciences Inc (FLNA) vs Paychex, Inc. (PAYX) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Paychex (PAYX) trades at $114.45, up 4.5% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 exceeding expectations, and maintains impressive profitability with 27.03% net income margin and 44.77% ROE. Recent dividend declaration of $1.19 per share and positive business developments including AI expansion support growth outlook.

While valuation metrics appear elevated with P/E of 22.49 and P/S of 6.08, Paychex's strong cash flow generation and market leadership position provide investment appeal. Key risks include competitive pressures and macroeconomic sensitivity to small business hiring trends. Analyst consensus remains cautious with only 16.67% buy ratings, though technical indicators suggest near-term bullish momentum.